[1] LI LJ, ZHONG ZH, CHEN QF, et al.FI-chemiluminescence determination of penicillamine[J]. Physical Testing and Chemical Analysis(Part B: Chemical Analysis)(理化检验-化学分册), 2008, 44(9): 868-870. [2] CHAPELA R, ZUNIGA G, SELMAN M.D-penicillamine in the therapy of fibrotic lung diseases[J]. Int J Clin Pharmacol Ther Toxicol, 1986, 24(1): 16-17. [3] DAVIS P.Penicillamine metal chelates and their possible importance in rheumatoid arthritis-a brief review[J]. Clin Invest Med, 1984, 7(1): 41-44. [4] KANG B, VERES-THORNER C, HEREDIA R, et al.Successful treatment of far-advanced progressive systemic sclerosis by D-penicillamine[J]. J Allergy Clin Immunol, 1982, 69(3): 297-305. [5] FIGUS A, ANGIUS A, LOUDIANOS G, et al.Molecular pathology and haplotype analysis of Wilson disease in Mediterranean populations[J]. Am J Hum Genet, 1995, 57(6): 1318-1324. [6] BULL PC, THOMAS GR, ROMMENS JM, et al.The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene[J]. Nat Genet, 1993, 5(4): 327-337. [7] HU WB, HAN YZ, XUE BC, et al.Epidemiological investigation of Wilson disease in Hanshan county Anhui Province[J]. Chin Med J(中华医学杂志), 2010, 91: 894-897. [8] YU MM, GAO ZW, CHEN XY, et al.Predicting pharmacokinetics of anti-cancer drug, famitinib in human using physiologically based pharmacokinetic model[J]. Acta Pharmaceutica Sinica(药学学报), 2014, 49(12): 1684-1688. [9] TSUME Y, AMIDON GL.The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation[J]. Mol Pharm, 2010, 7(4): 1235-1243. [10] WANG DL, TAO XH,ZHANG X, et al.HPLC-UV determination of penicillamine in human plasma[J]. Chinese Pharmacological Bulletin(中国药理学通报), 2013, 29(4): 585-588. |